IRMD
Neutral signalScored 2026-09-08 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
IRadimed Corporation
- Nom
- IRadimed Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $1.1B
- Employés
- 166
- PDG
- Roger E. Susi
- Site web
- https://www.iradimed.com
- Marché
- —
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 1 419 titres (~122 658,36 $ US)
- Insiders
- ALLEN MONTY K
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$34,972
Avg sell (VWAP, 90d window) $86.35 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-03
- Last synced
-
2026-09-09 09:58:02
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-03 | ALLEN MONTY K | Sell · S | 405 | $86.35 | $34,972 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-08 Drivers: fundamentals. Moteurs : fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 7.98 · operating margin 31%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | |
| Ebit Margin | 33.8% | 33.1% | 33.2% | 30.4% | 23.5% | |
| Ebitda Margin | 36.7% | 34.3% | 34.3% | 31.6% | 26.9% | |
| Operating Profit Margin | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | |
| Pretax Profit Margin | 33.8% | 33.1% | 33.2% | 30.4% | 23.5% | |
| Continuous Operations Profit Margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | |
| Net Profit Margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | |
| Bottom Line Profit Margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | |
| Current Ratio | 7.977 | 8.839 | 4.655 | 9.059 | 11.175 | |
| Quick Ratio | 6.835 | 7.617 | 3.870 | 8.431 | 10.545 | |
| Solvency Ratio | 1.756 | 1.743 | 0.866 | 1.140 | 1.002 | |
| Cash Ratio | 5.025 | 6.136 | 3.048 | 6.776 | 9.087 | |
| Price To Earnings Ratio | 54.960 | 36.184 | 34.904 | 27.735 | 60.803 | |
| Price To Earnings Growth Ratio | 3.342 | 3.076 | 1.047 | 0.811 | 0.103 | |
| Forward Price To Earnings Growth Ratio | 3.342 | 3.076 | 1.047 | 0.811 | 0.103 | |
| Price To Earnings Diluted Ratio | 55.589 | 36.667 | 35.163 | 27.735 | 62.446 | |
| Price To Earnings Diluted Growth Ratio | 3.335 | 3.300 | 1.087 | 0.733 | 0.109 | |
| Price To Book Ratio | 13.080 | 8.027 | 8.377 | 4.824 | 7.905 | |
| Price To Sales Ratio | 14.766 | 9.514 | 9.125 | 6.668 | 13.644 | |
| Price To Free Cash Flow Ratio | 72.029 | 39.551 | 109.615 | 43.513 | 54.250 | |
| Price To Operating Cash Flow Ratio | 49.609 | 27.195 | 44.431 | 35.389 | 50.676 | |
| Debt To Assets Ratio | 0.000 | 0.002 | 0.022 | 0.026 | 0.030 | |
| Debt To Equity Ratio | 0.000 | 0.002 | 0.029 | 0.030 | 0.034 | |
| Debt To Capital Ratio | 0.000 | 0.002 | 0.028 | 0.029 | 0.033 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.150 | 1.133 | 1.290 | 1.161 | 1.148 | |
| Working Capital Turnover Ratio | 1.217 | 1.159 | 1.020 | 0.771 | 0.652 | |
| Operating Cash Flow Ratio | 2.451 | 3.010 | 0.825 | 1.174 | 1.650 | |
| Operating Cash Flow Sales Ratio | 0.298 | 0.350 | 0.205 | 0.188 | 0.269 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.689 | 0.688 | 0.405 | 0.813 | 0.934 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 165.653 | 6.591 | 4.554 | 4.536 | |
| Capital Expenditure Coverage Ratio | 3.213 | 3.201 | 1.682 | 5.356 | 15.178 | |
| Dividend Paid And Capex Coverage Ratio | 1.094 | 1.182 | 0.634 | 0.696 | 15.178 | |
| Dividend Payout Ratio | 0.669 | 0.711 | 0.769 | 0.979 | 0.000 | |
| Enterprise Value Multiple | 38.595 | 25.696 | 24.465 | 17.782 | 45.450 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 76.8% | ▼-0.2% | ▼-0.1% |
| Ebit Margin | 33.8% | ▲0.7% | ▲3.0% |
| Ebitda Margin | 36.7% | ▲2.4% | ▲3.9% |
| Operating Profit Margin | 31.2% | ▲1.2% | ▲2.3% |
| Pretax Profit Margin | 33.8% | ▲0.7% | ▲3.0% |
| Continuous Operations Profit Margin | 26.8% | ▲0.6% | ▲1.7% |
| Net Profit Margin | 26.8% | ▲0.6% | ▲1.7% |
| Bottom Line Profit Margin | 26.8% | ▲0.6% | ▲1.7% |
| Current Ratio | 7.977 | ▼-0.863 | ▼-0.364 |
| Quick Ratio | 6.835 | ▼-0.782 | ▼-0.624 |
| Solvency Ratio | 1.756 | ▲0.013 | ▲0.455 |
| Cash Ratio | 5.025 | ▼-1.111 | ▼-0.989 |
| Price To Earnings Ratio | 54.961 | ▲18.776 | ▲12.043 |
| Price To Earnings Growth Ratio | 3.342 | ▲0.266 | ▲1.666 |
| Forward Price To Earnings Growth Ratio | 3.342 | ▲0.266 | ▲1.666 |
| Price To Earnings Diluted Ratio | 55.589 | ▲18.922 | ▲12.069 |
| Price To Earnings Diluted Growth Ratio | 3.335 | ▲0.035 | ▲1.623 |
| Price To Book Ratio | 13.080 | ▲5.053 | ▲4.638 |
| Price To Sales Ratio | 14.766 | ▲5.252 | ▲4.023 |
| Price To Free Cash Flow Ratio | 72.029 | ▲32.478 | ▲8.237 |
| Price To Operating Cash Flow Ratio | 49.609 | ▲22.414 | ▲8.149 |
| Debt To Assets Ratio | 0.000 | ▼-0.002 | ▼-0.016 |
| Debt To Equity Ratio | 0.000 | ▼-0.002 | ▼-0.019 |
| Debt To Capital Ratio | 0.000 | ▼-0.002 | ▼-0.018 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.150 | ▲0.017 | ▼-0.027 |
| Working Capital Turnover Ratio | 1.217 | ▲0.058 | ▲0.253 |
| Operating Cash Flow Ratio | 2.451 | ▼-0.560 | ▲0.629 |
| Operating Cash Flow Sales Ratio | 0.298 | ▼-0.052 | ▲0.035 |
| Free Cash Flow Operating Cash Flow Ratio | 0.689 | ▲0.001 | ▼-0.017 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▼-165.653 | ▼-36.267 |
| Capital Expenditure Coverage Ratio | 3.213 | ▲0.012 | ▼-2.513 |
| Dividend Paid And Capex Coverage Ratio | 1.094 | ▼-0.088 | ▼-2.663 |
| Dividend Payout Ratio | 0.669 | ▼-0.042 | ▲0.043 |
| Enterprise Value Multiple | 38.595 | ▲12.899 | ▲8.197 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.24B | $696.9M | $598.3M | $355.4M | $570.5M | |
| Enterprise value | $1.19B | $644.8M | $550.5M | $299.6M | $511.0M | |
| EV / Sales | 14.16x | 8.80x | 8.40x | 5.62x | 12.22x | |
| EV / Op. cash flow | 47.56x | 25.16x | 40.89x | 29.84x | 45.39x | |
| EV / Free cash flow | 69.05x | 36.59x | 100.87x | 36.69x | 48.59x | |
| EV / EBITDA | 38.59x | 25.70x | 24.46x | 17.78x | 45.45x | |
| Net debt / EBITDA | -1.66x | -2.08x | -2.12x | -3.31x | -5.29x | |
| Current ratio | 7.98x | 8.84x | 4.66x | 9.06x | 11.18x | |
| Income quality | 1.11x | 1.33x | 0.78x | 0.78x | 1.21x | |
| Graham number | $17 | $15 | $13 | $12 | $10 | |
| Graham net-net | $4 | $4 | $4 | $5 | $5 | |
| Tax burden | 79.3% | 79.2% | 79.1% | 79.3% | 94.8% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $71.0M | $66.7M | $59.7M | $68.9M | $69.4M | |
| Invested capital | $98.3M | $86.8M | $73.5M | $75.6M | $75.1M | |
| Return on assets | 20.7% | 19.6% | 18.7% | 15.0% | 11.3% | |
| Operating ROA | 25.3% | 23.1% | 22.6% | 18.6% | 12.8% | |
| Return on tangible assets | 21.3% | 20.2% | 19.2% | 15.4% | 11.4% | |
| Return on equity | 23.8% | 22.2% | 24.1% | 17.4% | 12.9% | |
| Return on invested capital | 21.0% | 19.3% | 20.8% | 16.0% | 12.2% | |
| Return on capital employed | 26.5% | 24.5% | 26.4% | 20.3% | 12.9% | |
| Earnings yield | 1.8% | 2.8% | 2.9% | 3.6% | 1.6% | |
| Free cash flow yield | 1.4% | 2.5% | 0.9% | 2.3% | 1.8% | |
| Capex / Op. cash flow | 31.1% | 31.2% | 59.5% | 18.7% | 6.6% | |
| Capex / Depreciation | 666.0% | 979.0% | 1046.4% | 279.6% | 52.7% | |
| Capex / Sales | 9.3% | 10.9% | 12.2% | 3.5% | 1.8% | |
| SG&A / Sales | 42.0% | 43.1% | 41.6% | 43.9% | 48.6% | |
| R&D / Sales | 3.5% | 3.9% | 4.4% | 4.3% | 4.6% | |
| Stock comp / Sales | 3.5% | 3.4% | 3.3% | 2.6% | 3.5% | |
| Intangibles / Total assets | 3.1% | 3.2% | 2.7% | 2.4% | 1.3% | |
| Days sales outstanding | 60d | 53d | 68d | 91d | 45d | |
| Days payables outstanding | 34d | 41d | 44d | 55d | 29d | |
| Operating cycle | 277d | 277d | 372d | 254d | 206d | |
| Cash conversion cycle | 243d | 236d | 328d | 199d | 176d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-04 iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100 On September 04, 2026, iRadimed Corp (IRMD) shares fell 3.8%, currently trading at $83.45. The stock has seen a notable decline, with a 52-week high of $107.90
- 2026-08-27 Algert Global LLC Sells 15,062 Shares of iRadimed Corporation $IRMD Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider''s stock after selling 15,062 shares during the period. Algert Global
- 2026-08-10 iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Moderate Buy” by Brokerages Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong
- 2026-07-31 iRadimed Q2 Earnings Call Highlights iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
- 2026-07-31 IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
- 2026-07-31 IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.
- 2026-07-24 IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026 ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.